

# HYPERFINE

## Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics

January 20, 2026

*Data presented at the annual American Society of Neuroimaging meeting supports clinical value and broad utility of the portable Swoop® system in outpatient neurology.*

GUILFORD, Conn.--(BUSINESS WIRE)--Jan. 20, 2026-- [Hyperfine, Inc.](#) (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the American Society of Neuroimaging (ASN) Annual Meeting in San Juan, Puerto Rico on January 16, 2026.

NEURO PMR (Neurological Evaluation in the Office with Portable MR) is the first prospective, multi-center, real-world study to evaluate the clinical utility and patient experience of portable MRI compared to standard-of-care MRI in outpatient neurology clinics. Two sites—DENT Neurologic Institute and Texas Neurology—enrolled 125 patients with neurologic conditions commonly seen in the outpatient setting, including headache, dementia, multiple sclerosis follow-up, and tumor surveillance. Patients received brain imaging on both the portable Swoop® system (0.064T) and a conventional high-field MRI (primarily 3T), enabling direct modality comparisons.

Portable MRI demonstrated 92% concordance with standard MRI in identifying the presence or absence of intracranial pathology during a blinded review by independent neuroradiologists. In unblinded paired image reviews incorporating clinical history, concordance increased to 98%, as assessed by a neurologist and neuroimager. Patients expressed a strong preference for portable MRI, reporting that they were four times more likely to choose it over standard MRI. Across all experience measures—including comfort, anxiety, claustrophobia, noise, and overall satisfaction—portable MRI was rated superior to standard MRI ( $p < 0.0001$ ). Trained clinical staff successfully operated the system within neurology offices without the need for MR technologists, highlighting its safe and simple workflow.

"From a clinical perspective, I have been impressed by the image quality delivered by the Swoop® system. The study results give me confidence in its ability to detect structural abnormalities encountered in routine neurological care," said Laszlo Mechtler, MD, Chief Medical Officer at DENT Neurologic Institute and Principal Investigator of the NEURO PMR study. "Portable MRI represents a groundbreaking innovation for neurology clinics, complementing tools like EEG and ultrasound to expand diagnostic capabilities at the point of care. Neuroimaging is not merely an ancillary test but an extension of the neurological examination—expanding access to this technology will put imaging back into the neurologist's hands and meaningfully improve the quality of patient care."

The Swoop® system addresses challenges that have historically prevented neurology practices from bringing MRI on-site. It is portable, fits in an exam room, requires no specialized sitting, shielding, or helium, and plugs into a standard outlet. Scans can be performed by existing clinic staff and are eligible for reimbursement under existing brain MRI CPT codes after site accreditation.

"The NEURO PMR results validate the transformative role portable MRI can play in expanding imaging beyond traditional hospital settings," said Chi Nguyen, Senior Vice President of Office & Community Business at Hyperfine. "By removing the economic and operational barriers of conventional MRI, the Swoop® system empowers neurology practices to deliver safe and convenient imaging in the clinic. This is a win for physicians, who gain timely diagnostic insights; a win for patients, who enjoy a better imaging experience; and a win for the healthcare system, which benefits from efficient, cost-effective care delivery."

For more information about the Swoop® system, please visit [HyperfineMRI.com](#).

### About the Swoop® Portable MRI Systems

The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

### About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit [HyperfineMRI.com](#).

The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc.

### Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance, and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and

uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq Stock Market; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to progress on product advancements and improvements; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; anticipated National Institutes of Health funding pressures; the effect of U.S. export controls and tariffs; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260120756787/en/): <https://www.businesswire.com/news/home/20260120756787/en/>

**Media**

Devin Zell  
Hyperfine  
[dzell@hyperfine.io](mailto:dzell@hyperfine.io)

**Investor**

Webb Campbell  
Gilmartin Group LLC  
[webb@gilmartinir.com](mailto:webb@gilmartinir.com)

Source: Hyperfine, Inc.